Literature DB >> 12169274

Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-beta(1)-induced fibrogenesis in skin fibroblasts.

Krista Rombouts1, Toshiro Niki, Patricia Greenwel, Alain Vandermonde, Annemie Wielant, Karine Hellemans, Pieter De Bleser, Minoru Yoshida, Detlef Schuppan, Marcos Rojkind, Albert Geerts.   

Abstract

Excessive production of collagens by alpha-smooth muscle actin (alpha-SMA)-positive myofibroblasts leads to fibrotic skin diseases, such as hypertrophic scarring. This process is characterized by an imbalance between extracellular matrix (ECM) synthesis and degradation, while transforming growth factor beta (TGF-beta(1)), known to be a key mediator of fibrogenesis, is up-regulated. In this study we have investigated the possible antifibrogenic effect of Trichostatin A (TSA), a histone deacetylase inhibitor, on rat skin fibroblasts in culture. mRNA steady-state levels and de novo protein synthesis of procollagen types I and III and alpha-SMA were inhibited when skin fibroblasts were treated with 100 nM TSA with or without TGF-beta(1). While the transcription rate of the procollagen alpha1(I) gene was increased following TSA or TGF-beta(1) treatment, TSA abrogated the stimulatory effect of TGF-beta(1) on procollagen alpha1(I) transcription when both compounds were added simultaneously. The reduction of procollagen alpha1(I) and alpha1(III) mRNA steady-state levels by TSA did not require de novo protein synthesis, while the effect of TSA on alpha-SMA mRNA steady-state levels was cycloheximide-sensitive. Interestingly, TSA affected TGF-beta(1) and its downstream mediators, i.e., the Smad family proteins. TSA strongly induced in a biphasic way the expression of 5'TG3' interacting factor (TGIF), a known endogenous corepressor molecule of the TGF-beta(1) signaling pathway. Addition of exogenous TGF-beta(1) did not interfere with the effect of TSA on the TGIF mRNA level. Our study shows that inhibition of histone deacetylases by TSA reduces expression of fibrosis-related genes in skin fibroblasts and this coincides by alterations in the TGF-beta(1) signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12169274     DOI: 10.1006/excr.2002.5577

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  40 in total

1.  Somatostatin at nanomolar concentration reduces collagen I and III synthesis by, but not proliferation of activated rat hepatic stellate cells.

Authors:  Hendrik Reynaert; Krista Rombouts; Yutao Jia; Daniel Urbain; Nirjhar Chatterjee; Naoki Uyama; Albert Geerts
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

Review 2.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

3.  The Scar-in-a-Jar: studying potential antifibrotic compounds from the epigenetic to extracellular level in a single well.

Authors:  C Z C Chen; Y X Peng; Z B Wang; P V Fish; J L Kaar; R R Koepsel; A J Russell; R R Lareu; M Raghunath
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

4.  Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy.

Authors:  Yongli Kong; Paul Tannous; Guangrong Lu; Kambeez Berenji; Beverly A Rothermel; Eric N Olson; Joseph A Hill
Journal:  Circulation       Date:  2006-05-30       Impact factor: 29.690

5.  Aminoguanidine reduces diabetes-associated cardiac fibrosis.

Authors:  Fernando Magdaleno; Chuck Christopher Blajszczak; Claudia Lisette Charles-Niño; Alma Marlene Guadrón-Llanos; Alan Omar Vázquez-Álvarez; Alejandra Guillermina Miranda-Díaz; Natalia Nieto; María Cristina Islas-Carbajal; Ana Rosa Rincón-Sánchez
Journal:  Exp Ther Med       Date:  2019-08-20       Impact factor: 2.447

6.  Dynamic Regulation of Integrin α6β4 During Angiogenesis: Potential Implications for Pathogenic Wound Healing.

Authors:  Diana Desai; Purva Singh; Livingston Van De Water; Susan E Laflamme
Journal:  Adv Wound Care (New Rochelle)       Date:  2013-10       Impact factor: 4.730

7.  Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin.

Authors:  Fang Liu; Mark D Levin; Nataliya B Petrenko; Min Min Lu; Tao Wang; Li Jun Yuan; Andrea L Stout; Jonathan A Epstein; Vickas V Patel
Journal:  J Mol Cell Cardiol       Date:  2008-09-16       Impact factor: 5.000

8.  Inhibition of histone deacetylase 2 mitigates profibrotic TGF-β1 responses in fibroblasts derived from Peyronie's plaque.

Authors:  Ji-Kan Ryu; Woo-Jean Kim; Min-Ji Choi; Jin-Mi Park; Kang-Moon Song; Mi-Hye Kwon; Nando-Dulal Das; Ki-Dong Kwon; Dulguun Batbold; Guo-Nan Yin; Jun-Kyu Suh
Journal:  Asian J Androl       Date:  2013-06-17       Impact factor: 3.285

Review 9.  Emerging role of epigenetics in systemic sclerosis pathogenesis.

Authors:  M Ciechomska; J M van Laar; S O'Reilly
Journal:  Genes Immun       Date:  2014-07-17       Impact factor: 2.676

10.  Histone deacetylase inhibitors attenuate P-aIgA1-induced cell proliferation and extracellular matrix synthesis in human renal mesangial cells in vitro.

Authors:  Qin Dai; Jian Liu; Yun-lei Du; Xu Hao; Ji Ying; Yun Tan; Li-qun He; Wei-ming Wang; Nan Chen
Journal:  Acta Pharmacol Sin       Date:  2016-01-18       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.